| Item Type | Name |
|
Concept
|
Diabetes Mellitus
|
|
Concept
|
Diabetes Mellitus, Type 1
|
|
Concept
|
Diabetes Mellitus, Type 2
|
|
Academic Article
|
Advantages of extended-release metformin in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Management of diabetes mellitus in the elderly.
|
|
Academic Article
|
Exenatide once weekly in type 2 diabetes mellitus.
|
|
Academic Article
|
Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
|
|
Academic Article
|
Collaboration designed to increase translation of diabetes research outcomes into clinical practice.
|
|
Academic Article
|
Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
|
|
Academic Article
|
Diabetes knowledge: are resident physicians and nurses adequately prepared to manage diabetes?
|
|
Academic Article
|
A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS.
|
|
Academic Article
|
SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
|
|
Academic Article
|
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes?
|
|
Academic Article
|
Incidence and severity of pancreatogenic diabetes after pancreatic resection.
|
|
Academic Article
|
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
|
|
Academic Article
|
Durability of response to dapagliflozin: a review of long-term efficacy and safety.
|
|
Academic Article
|
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
|
|
Academic Article
|
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
|
|
Academic Article
|
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
|
|
Academic Article
|
Evaluation of an Ongoing Diabetes Group Medical Visit in a Family Medicine Practice.
|
|
Academic Article
|
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
|
|
Academic Article
|
Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014.
|
|
Academic Article
|
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
|
|
Academic Article
|
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
|
|
Academic Article
|
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
|
|
Academic Article
|
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
|
|
Academic Article
|
Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.
|
|
Academic Article
|
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
|
|
Academic Article
|
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
|
|
Academic Article
|
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
|
|
Academic Article
|
SGLT2 inhibitors.
|
|
Academic Article
|
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52?weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
|
|
Academic Article
|
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
|
|
Academic Article
|
Assessing the impact of medically tailored meals and medical nutrition therapy on type 2 diabetes: Protocol for Project MiNT.
|
|
Academic Article
|
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice.
|
|
Academic Article
|
Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis.
|
|
Academic Article
|
Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis.
|
|
Academic Article
|
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.
|
|
Academic Article
|
Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
|
|
Academic Article
|
Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?
|
|
Academic Article
|
Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
|
|
Academic Article
|
Type 2 diabetes and HbA1c goal: time for individualised therapy.
|
|
Academic Article
|
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
|
|
Academic Article
|
Uncontrolled diabetes mellitus.
|